Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ: EVO), as per information from Reuters. This news catalyzed a 22% surge in Evotec’s shares on Monday, reflecting market anticipation of the potential deal.
Triton’s Interest and Shareholding
Triton Partners has been in the process of engaging with senior executives at Evotec, exploring the feasibility of a buyout, according to sources privy to the discussions. Recent regulatory filings indicate that Triton has escalated its ownership in Evotec to 9.99%, securing its position as the largest shareholder.
Major Shareholder Endorsement Required
For Triton to escalate its shareholding beyond 10%, endorsements from Evotec’s other significant shareholders, including Novo Nordisk (NYSE: NVO), parent company Novo Holdings, and Mubadala Investment, are crucial. Evotec has stated that Triton’s stake-building has not influenced its daily operations, maintaining a clear distinction between corporate actions and business continuity.-Fineline Info & Tech
Leave a Reply